In Response
- PMID: 33449569
- DOI: 10.1213/ANE.0000000000005280
In Response
Conflict of interest statement
Conflicts of Interest: The faculty received reimbursement for travel expenses attending the meeting. No honorarium was provided. T. J. Gan: Honoraria from Acacia, Edwards, Masimo, Medtronic, Merck and Mallinckrodt. S. Bergese: Acacia (Funding for Clinical Trial to Ohio State University). F. Chung has received research support from the Ontario Ministry of Health and Long-Term Care, University Health Network Foundation, Acacia Pharma, Medtronics grants to institution outside of the submitted work, Up-to-date royalties, STOP-Bang proprietary to University Health Network. Speaker honorarium from Baxter Pharma. P. Diemunsch: Ambu: Member of an advisors panel on airway management, Fisher & Paykel: Research Grants, paid conferences, French Government: Expert at the Court of Appeal, Acacia Pharma: Research Grants, MSD: Member of an advisory panel on ERAS. A. S. Habib: Funded Research: Pacira Biosciences, Avanos Medical Inc., Advisory Board: Takeda. A. L. Kovac: Merck (speaker’s bureau), Helsinn (speaker’s bureau), Mundipharma (speaker’s bureau), Acacia (speaker’s bureau). T. A. Meyer: Acacia, Neumentum. R. D. Urman: Merck (research funding); Medtronic (consulting fees and research funding); Takeda (consulting fees); Acacia (consulting fees and research funding); Posimir (consulting fees). S. Ayad: Pacira, Medtronic and Acacia. K. Candiotti: Research support-Acacia, Pfizer, Takeda; Consulting-Acacia, Pfizer, Takeda. T. L. Hedrick: MedEdicus. P. Kranke acted as investigator in phase III trials on amisulpride during the last 3 years. He gave invited lectures for FreseniusKabi (propofol), Grünenthal, CSL-Behring, TevaRatiopharm. H. S. Minkowitz: Acacia, AcelRX, Adynxx, Concentric, Durect, Heron, Merck, Mallinckrodt, Innocoll, Pacira, Neumentum, Westward, Trevena, Takeda. J. Morton: Medtronic, Olympus, Novo Nordisk.
Comment on
-
Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting.Anesth Analg. 2020 Aug;131(2):411-448. doi: 10.1213/ANE.0000000000004833. Anesth Analg. 2020. PMID: 32467512 Review.
-
Oral Perphenazine 8 mg: A Low-Cost, Efficacious Antiemetic Option.Anesth Analg. 2021 Feb 1;132(2):e29-e31. doi: 10.1213/ANE.0000000000005279. Anesth Analg. 2021. PMID: 33449568 Free PMC article. No abstract available.
References
-
- Williams BA, Holder-Murray JM, Esper SA, et al. Oral perphenazine 8 mg: a low-cost, efficacious antiemetic option. Anesth Analg. 2021;132:e29–e31.
-
- Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2020;131:411–448.
-
- Williams BA, Kentor ML, Skledar SJ, Orebaugh SL, Vallejo MC. Routine multimodal antiemesis including low-dose perphenazine in an ambulatory surgery unit of a university hospital: a 10-year history. Supplement to: Eliminating postoperative nausea and vomiting in outpatient surgery with multimodal strategies including low doses of nonsedating, off-patent antiemetics: Is “zero tolerance” achievable? ScientificWorldJournal. 2007;7:978–986.
-
- Holder-Murray J, Esper SA, Boisen ML, et al. Postoperative nausea and vomiting in patients undergoing colorectal surgery within an institutional enhanced recovery after surgery protocol: comparison of two prophylactic antiemetic regimens. Korean J Anesthesiol. 2019;72:344–350.
-
- Schnabel A, Eberhart LH, Muellenbach R, Morin AM, Roewer N, Kranke P. Efficacy of perphenazine to prevent postoperative nausea and vomiting: a quantitative systematic review. Eur J Anaesthesiol. 2010;27:1044–1051.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources